← The Wire
SMMTNasdaq
Summit Therapeutics Inc.
Pharmaceutical Preparations · CIK 1599298
Summit Therapeutics develops and commercializes novel oncology medicines, including ivonescimab, to treat serious unmet medical needs
🔥 High media attention
$10.87B
Market cap
$14.32
Last close
+2.2%
1D
+0.3%
5D
6.0M
Volume
Price · last 39 sessions-15.7%
May 4L $13.05 · H $18.95Jun 29
292
Total filings
Jun 12, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 12, 20268-KReg FD DisclosureJun 11, 2026424B5424B5Jun 10, 20268-KCompany UpdateJun 3, 20268-KCompany UpdateJun 1, 202610-Q10-QApr 30, 20268-KResults of OperationsApr 30, 2026DEFA14ADEFA14AApr 17, 2026DEF 14ADEF 14AApr 17, 202610-K10-KFeb 23, 20268-KResults of Operations · Reg FD DisclosureFeb 23, 20268-KCompany UpdateJan 29, 20268-KResults of Operations · Reg FD DisclosureJan 12, 20268-KCompany UpdateNov 7, 20258-KMaterial Agreement · Equity IssuanceOct 22, 202510-Q10-QOct 20, 20258-KResults of Operations · Company UpdateOct 20, 20258-KCompany UpdateSep 8, 20258-KResults of OperationsAug 11, 20258-KMaterial AgreementAug 11, 2025424B5424B5Aug 11, 202510-Q10-QAug 11, 20258-KMaterial AgreementJun 20, 20258-KShareholder VoteJun 17, 20258-KCompany UpdateMay 30, 202510-Q10-QMay 1, 20258-KResults of Operations · Reg FD DisclosureMay 1, 2025DEF 14ADEF 14AApr 29, 20258-KCompany UpdateApr 25, 20258-KCompany UpdateApr 23, 202510-K10-KFeb 24, 20258-KResults of Operations · Reg FD DisclosureFeb 24, 20258-KExecutive Change · Company UpdateJan 24, 20258-KResults of Operations · Reg FD DisclosureJan 13, 202510-Q10-QOct 30, 20248-KResults of Operations · Reg FD DisclosureOct 30, 20248-KMaterial Agreement · Equity IssuanceSep 12, 20248-KReg FD Disclosure · Company UpdateSep 9, 202410-Q10-QAug 6, 20248-KResults of Operations · Reg FD DisclosureAug 6, 20248-KExecutive Change · Material AgreementJun 27, 20248-KExecutive Change · Shareholder VoteJun 17, 2024DEFA14ADEFA14AJun 13, 20248-KMaterial Agreement · Equity IssuanceJun 3, 20248-KReg FD Disclosure · Company UpdateJun 3, 20248-KCompany UpdateMay 30, 20248-KCompany UpdateMay 24, 20248-KMaterial AgreementMay 13, 2024424B5424B5May 13, 20248-KResults of OperationsMay 1, 202410-Q10-QMay 1, 2024DEF 14ADEF 14AApr 25, 20248-KExecutive ChangeApr 11, 20248-KExecutive ChangeApr 3, 20248-KCompany UpdateMar 22, 20248-KReg FD DisclosureMar 12, 20248-KCompany UpdateMar 5, 20248-KResults of OperationsFeb 20, 202410-K10-KFeb 20, 20248-KReg FD DisclosureFeb 15, 20248-KCompany UpdateFeb 8, 20248-KResults of Operations · Reg FD DisclosureJan 8, 20248-KCompany UpdateJan 3, 202410-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KCompany UpdateOct 31, 20238-KExecutive Change · Material AgreementOct 16, 2023DEF 14ADEF 14ASep 19, 202310-Q10-QAug 9, 20238-KResults of OperationsAug 9, 20238-KResults of OperationsAug 2, 20238-KReg FD DisclosureJun 5, 20238-KCompany UpdateJun 1, 20238-KShareholder VoteMay 25, 20238-KResults of OperationsMay 11, 202310-Q10-QMay 11, 20238-KCompany UpdateMay 9, 20238-KCompany UpdateMay 3, 2023DEF 14ADEF 14AApr 21, 20238-KCompany UpdateMar 17, 2023
Insider Activity
◆ Cluster Buy · 3 insidersIn the 90 days to Oct 21, 2025: 3 insiders bought $11.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 21, 2025 | Xia YuDirector | Buy | 533,617 | $18.74 | $10.0M |
| Oct 21, 2025 | Duggan Robert WCo-Chief Executive Officer | Buy | 26,680 | $18.74 | $500K |
| Oct 21, 2025 | Zanganeh MahkamCo-Chief Executive Officer | Buy | 26,680 | $18.74 | $500K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 1 reputable article · skews ▼ negative.
CNBCA hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China1mo agoBarron'sS&P 500 Futures Climb in Premarket Trading; WR Berkley, Summit Therapeutics Lag1mo ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance